Protocol Page


	Study ID (Protocol Number)
	AI424-451


	STUDY LOCATIONS*
	Children's National Medical Center Washington, District of Columbia 20010 Recruiting
	Suny Upstate Medical University Syracuse, NY 13210 Recruiting
	*Not all study site locations may be listed - please check back soon for updated information. For more information regarding other participating countries, please visit clinicaltrials.gov.

	STUDY NAME
	Phase IIIB Pediatric ATV Powder for Oral Use (POU) (PRINCE2)
	STUDY OVERVIEW
	The purpose of this study is to describe the safety, efficacy and pharmacokinetic profile of a regimen consisting of Atazanavir powder boosted with Ritonavir liquid and an optimized dual Nucleoside Reverse Transcriptase Inhibitor (NRTI) backbone in pediatric subjects ≥ 3 months to < 8 years of age.

The study information provided here is a portion of what is available on ClinicalTrials.gov. Please visit ClinicalTrials.gov for complete information about this and other clinical studies.